NEW YORK (GenomeWeb) – Molecular diagnostics developer Exact Sciences announced today that it plans to offer 8.5 million shares of common stock for sale at $15.50 a share.

The company — which earlier this week said it would offer 7 million shares but raised the amount of the offering because of market demand — said it will use the proceeds for general corporate and working capital purposes, to fund the development of new products, and to fund the commercialization of its Cologuard colorectal cancer test.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.